CMEA Capital is a venture capital firm located in San Francisco, California. The firm was founded in 1989 as a $40M fund entitled “Chemical and Materials Enterprise Associates”. CMEA’s early focus was on investing in startup enterprises that commercialized new applications of specialty chemicals and materials technologies. Twenty-four years later, CMEA Capital has raised six additional funds and currently has $1.1 billion under management.

Currently, CMEA Capital focuses on both early and late stage science-focused ventures in the following sectors: life sciences, high technology, energy and materials. Notable investments include Biomimetic Therapeutics (acquired by Wright Medical Group), Flextronics, MacroGenics (NASDAQ:MGNX), Myogen (acquired by Gilead Sciences), Solaria and Symyx (NASDAQ:SMMX).